{"database": "lobbying", "table": "lobbying_activities", "rows": [[1266176, "79271210-134a-4b94-aac8-083981f42251", "Q2", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "ONYX PHARMACEUTICALS", 2012, "second_quarter", "MED", "Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages.  HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 30000, null, 0, 0, "2012-07-17T13:09:54.003000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1266176"], "units": {}, "query_ms": 2.8973339940421283, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}